Interrad Medical today announced that it received an Innovative Technology contract from Vizient for its SecurAcath technology.
The Innovative Technology program by Vizient identifies medical devices that can improve clinical care and enhance the business model for healthcare organizations. It gives device companies visibility in Vizient’s catalog of awarded contracts to allow members of the program to evaluate and choose devices based on their needs.
Vizient is a healthcare performance improvement company that serves 97% of the U.S.’s academic medical centers, so the deal will allow Interrad Medical to boost its market share in the hospital market.
SecurAcath is a subcutaneous catheter securement device that reduces the risk of catheter-related infections, decreases catheter dislodgment and migration, decreases catheter replacement costs and lowers the total cost of patient care.
“We are very pleased the SecurAcath has been recognized by the experts to receive the Innovative Technology contract,” said Joe Goldberger, president and CEO of Interrad Medical. “We look forward to offering SecurAcath to the full Vizient membership through this contract to enhance clinical and patient care with this important medical technology.”
The new contract follows Interrad Medical’s recent announcement of a strategic partnership with Eloquest Healthcare to expand sales of SecurAcath in the U.S.
